Kayothera specializes in inhibiting two of the last remaining nuclear receptors pathways to be drugged – the retinoid and rexinoid nuclear receptors. These pathways are clinically validated to drive adverse cardiometabolic and cancer outcomes, yet have no available inhibitors – until now. 

Kayothera’s unique approach blocks the formation of the retinoid or rexinoid nuclear ligands with novel, orally-available small molecules that have proven to be safe and effective therapies.  We are developing these medicines to provide patients with new options for managing diabetes, obesity and additional unmet medical needs.